Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
191/433 Publications
-
Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.
-
Toward non-invasive assessment strategies in autoimmune hepatitis.
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
-
Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.
-
Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.
-
Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Review
-
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.
-
Response to: Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications, by Jerome Boursier et al.
-
The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).
-
Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
-
Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.
-
Non-invasive diagnosis and follow-up of portal hypertension.
-
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
-
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.
-
Biomarkers for liver disease in urea cycle disorders.
-
Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.
-
Hepatoprotective Effect of Antrodia cinnamomea Mycelium in Patients with Nonalcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
-
Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. Review
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.
-
Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
-
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
-
The non-invasive assessment of hepatic fibrosis.
-
Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.
-
Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
-
Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis.
-
Noninvasive diagnosis in alcohol-related liver disease. Review
-
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
-
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
-
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
-
Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.
-
Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review
-
Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.
-
Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.
-
Diagnostic accuracy of the Coopscore© to predict liver fibrosis in human immunodeficiency virus/hepatitis B virus co-infection.
-
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
-
Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German Obesity Society.
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
-
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
-
A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases.
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
-
Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest - comparison with histopathological assessment.
-
Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.
-
Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
-
Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Management of the patient with SVR. Review
-
Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.
-
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B.
-
Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.
-
Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.
-
Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review.
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.
-
Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.
-
Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.
-
Personalized management of cirrhosis by non-invasive tests of liver fibrosis.
-
Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.
-
Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
-
Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B.
-
Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.
-
Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
-
Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.
-
Hepatitis B: are non-invasive markers of liver fibrosis reliable?
-
Liver fibrosis markers in alcoholic liver disease.
-
Non-invasive diagnosis of hepatitis B virus-related cirrhosis.
-
Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C.
-
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
-
The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy.
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
-
[Biomarkers for liver fibrosis: advances, advantages and disadvantages].
-
[Prognosis assessment of alcoholic liver disease: how and why?].
-
[The value of noninvasive serological markers in hepatitis B].
-
Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
-
Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.
-
Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C.
-
Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.
-
Evaluation of liver stiffness measurement by fibroscan as compared to liver biopsy for assessment of hepatic fibrosis in children with chronic hepatitis C.
-
Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy.
-
Noninvasive evaluation of NAFLD.
-
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.
-
Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation.
-
Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
-
Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.
-
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.
-
Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C.
-
Comparison of noninvasive models of fibrosis in chronic hepatitis B.
-
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.
-
Diagnostic algorithms for liver fibrosis in hepatitis C: are they ready to avoid liver biopsy?
-
Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study.
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
-
Non-invasive evaluation of liver fibrosis in chronic hepatitis C.
-
Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.
-
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
-
Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.
-
Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.
-
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.
-
Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C.
-
Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.
-
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
-
FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.
-
First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.
-
Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load.
-
Non-invasive markers for hepatic fibrosis.
-
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
-
Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers.
-
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
-
Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.
-
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
-
The risk of multiplying diagnostic combinations in the absence of a perfect gold standard for a fibrosis test.
-
Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.
-
ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure.
-
Altered serum N-glycomics in chronic hepatitis B patients.
-
Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.
-
Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.
-
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.
-
Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.
-
Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.
-
Diagnosis of fibrosis and cirrhosis. Liver biopsy is not always necessary.
-
Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).
-
Fibrotest or Fibroscan for evaluation of liver fibrosis in haemophilia patients infected with hepatitis C.
-
Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
-
Non-invasive assessment of liver fibrosis: are we ready?
-
Optimization and robustness of blood tests for liver fibrosis and cirrhosis.
-
Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.
-
An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.
-
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
-
Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.
-
Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.
-
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication
-
Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.
-
Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
-
GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics.
-
Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C.
-
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication
-
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
-
The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.
-
The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.
-
The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
-
The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calès et al. Gastroenterol Clin Biol 2008;32:1050-60: "Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests".
-
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.
-
Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Key publication
-
Assessment of liver fibrosis: noninvasive means.
-
Biomarkers of liver fibrosis.
-
Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.
-
Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C.
-
Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests.
-
Implementing non-invasive markers for liver fibrosis in clinical practice.
-
Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients.
-
Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection.
-
The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases.
-
The use of enzyme results for liver fibrosis evaluation neccessitates standardization.
-
Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.
-
Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.
-
Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C.
-
External validation of FibroIndex.
-
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.
-
FibroMAX: towards a new universal biomarker of liver disease?
-
Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.
-
Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy.
-
Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.
-
Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.
-
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.
-
Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.
-
FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients.
-
Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.
-
Progression of liver fibrosis among injection drug users with chronic hepatitis C.
-
Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.
-
Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
-
A novel panel of blood markers to assess the degree of liver fibrosis.
-
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.
-
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.
-
Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.
-
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.
-
Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.
-
Noninvasive prediction of fibrosis in patients with chronic hepatitis C.
-
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
-
Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.
-
Acoustic Radiation Force Impulse Imaging for Diagnosis and Monitoring of Liver Fibrosis in Patients with Hepatitis C: A review of diagnostic accuracy, clinical effectiveness,…
-
Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
-
Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication
Showing the full result list. The page is server-rendered and not paginated.